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A B S T R A C T   
Clotrimazole is a non-prescription and broad-spectrum antifungal drug sold under brand names such as Can-
esten® and Lotrimin®. It is used to treat different types of fungal infections, from oral thrush to athlete’s foot and 
vaginal mycosis. The level of exposure to clotrimazole is uncertain, as the exact usage amongst self-medicating 
patients is unclear. Recent studies have raised potential concern about the unsupervised use of clotrimazole 
during pregnancy, especially since it is a potent inhibitor of CYP enzymes of the steroidogenesis pathway. To 
address some of these concerns, we have assessed the effects of intrauterine exposure to clotrimazole on 
developing rat fetuses. By exposing pregnant rats to clotrimazole 25 or 75 mg/kg bw/day during gestation days 
7–21, we obtained internal fetal concentrations close to those observed in humans. These in vivo data are in 
strong agreement with our physiologically-based pharmacokinetic (PBK)-modelled levels. At these doses, we 
observed no obvious morphological changes to the reproductive system, nor shorter male anogenital distance; a 
well-established morphometric marker for anti-androgenic effects in male offspring. However, steroid hormone 
profiles were significantly affected in both maternal and fetal plasma, in particular pronounced suppression of 
estrogens was seen. In fetal testes, marked up-concentration of hydroxyprogesterone was observed, which in-
dicates a specific action on steroidogenesis. Since systemic clotrimazole is rapidly metabolized in humans, 
relevant exposure levels may not in itself cause adverse changes to the reproductive systems. Its capacity to 
significantly alter steroid hormone concentrations, however, suggests that clotrimazole should be used with 
caution during pregnancy.   
1. Introduction 
Developmental exposures to endocrine disrupting chemicals (EDCs) 
are associated with a string of reproductive disorders in humans, from 
genital malformations at birth to reproductive cancers and infertility in 
adulthood (Johansson et al., 2017; Skakkebaek et al., 2016). Animal 
studies have confirmed these associations and established clear links 
between compromised hormone signaling and adverse reproductive 
outcomes. The list of suspected EDCs now comprises a large number of 
chemical substances, including industrial chemicals such as phthalates 
and parabens, pesticides including azole fungicides, and also 
pharmaceutical drugs. 
Non-prescription medicines harboring endocrine disrupting proper-
ties may be of particular concern to the unborn child. This is because the 
use of non-prescription medicines reportedly is widespread and in some 
instances very substantial, prompting researchers to raise the alarm over 
for instance the indiscriminate use of mild-analgesics during pregnancy 
(Kristensen et al., 2016). Besides analgesics, non-prescription anti- 
fungal medications containing azoles are used indiscriminately during 
pregnancy. Since many azoles have endocrine disrupting properties 
(Draskau et al., 2019; Goetz et al., 2007; Hass et al., 2012; Kjærstad 
et al., 2010; Laier et al., 2006; Melching-Kollmuss et al., 2017; Roelofs 
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et al., 2014; Taxvig et al., 2008, 2007; Vinggaard et al., 2005), it raises 
the questions if non-prescription azole fungicides themselves are endo-
crine disruptors and if they could pose a risk to a developing child at 
relevant exposure doses. One example is clotrimazole, a broad-spectrum 
antifungal azole drug that could potentially cause anti-androgenic ef-
fects in human male fetuses (Mogensen et al., 2017). 
Clotrimazole is used to treat different fungal infections such as oral 
thrush, diaper rash, athlete’s foot and vaginal mycosis (Crowley and 
Gallagher, 2014). It is sold over-the-counter under various trade names 
(e.g. Canesten® and Lotrimin®). Exact usage amongst self-medicating 
patients, and thus human exposure to clotrimazole is not clear. Its use 
is considered safe, however, with low absorption levels from topical 
applications and rapid metabolism once absorbed. For instance, internal 
blood concentrations in women after vaginal treatment with clotrima-
zole vaginal tablets is estimated to be only 3–10% of the dose concen-
tration (Munkboel et al., 2019; Ritter et al., 1982). Worryingly though, a 
recent study puts this assumption of safety into question as it shows 
clotrimazole to be a very potent disruptor of human steroidogenesis in 
vitro, even at concentrations below those observed in women after 
vaginal application (Munkboel et al., 2019). These data, coupled with 
preliminary outcomes from an epidemiological study reporting a (non- 
statistically significant) association between clotrimazole exposure and 
a shorter anogenital distance (AGD) in human male offspring (Mogensen 
et al., 2017) warrants further investigations. Especially since a short 
AGD in male new-borns is an established biomarker for incomplete 
masculinization caused by suppressed androgen action during fetal life, 
an effect that can lead to various male reproductive disorders (Schwartz 
et al., 2019). In other words, is the relatively indiscriminate use of clo-
trimazole during pregnancy unproblematic, or should there be tighter 
regulations or warnings for pregnant women? To investigate this 
further, we designed an intrauterine exposure study in rats with a clear 
focus on characterizing potential endocrine disrupting effects in the 
developing fetus, including pharmacokinetic considerations; measured 
and modelled. 
2. Materials and methods 
2.1. Chemicals 
The test substance used in this study was clotrimazole (≥98% pure, 
CAS no.: 23593–75-1, product no.: C6019, lot no.:039M4778V) pur-
chased from Sigma-Aldrich (MO, US). Acetonitrile, methanol, formic 
acid, ethyl acetate and 25% ammonium hydroxide, all LC-MS grade, 
were purchased from Sigma Aldrich (Schneldorf, Germany). Isolute bulk 
C-18 sorbent was purchased from Biotage, (Uppsala, Sweden) and 
washed with acetonitrile and ethyl acetate and dried prior to use. A Milli 
Q system (Millipore Corporation, US) was used for water purification. 
2.2. Androgen receptor (AR) reporter gene assay 
Clotrimazole (Sigma Aldrich, MO, US, CAS no.: 23593–75-1) was 
used to prepare a stock solution of 100 mM prepared in DMSO. The stock 
was visually inspected to verify solubility. 
The AR reporter gene assay was performed as previously described 
(Draskau et al., 2019) using the AR-EcoScreen cell line from the JCRB 
Cell Bank (cat. no. JCRB1328). These cells are stably transfected with 
the human AR, as well as an androgen-dependent reporter plasmid and a 
constitutive reporter plasmid as described in the OECD guideline no. 458 
(OECD, 2016). We measured both agonistic and antagonistic activity, as 
well as effects on cell viability. Cell culture was performed in DMEM-F12 
medium without phenol red (Life Technologies, CA, US) supplemented 
with 5% FBS (Life Technologies, CA, US), 50 units/mL penicillin, 50 μg/ 
mL streptomycin (Life Technologies, CA, US), 200 μg/mL Zeocin 
(Invivogen, CA, US), and 100 μg/mL Hygromycin (Invitrogen, CA, US) 
in a humidified atmosphere at 37 ◦C with 5% CO2. During experiments, 
the same medium was used; however, Zeocin and Hygromycin was 
removed and FBS exchanged for 5% DCC-FBS (Sigma Aldrich, MO, US). 
Cells were seeded at 9000 cells/well in clear-bottomed 96-well plates 
(Costar, Corning, NY, US). After 24 h, clotrimazole was added at con-
centrations ranging from 0.01–3.1 μM, based on a range finding study 
showing compromised cell viability at higher concentrations (data not 
shown). In the antagonist mode, cells were co-treated with 0.1 nM 
R1881 (PerkinElmer, MA, US) - a synthetic AR agonist – in a concen-
tration approximately corresponding to the EC50-value based on his-
torical data (Rosenmai et al., 2021). Finally, R1881 and the AR 
antagonist hydroxyflutamide (OHF, Toronto Research Chemicals, ON, 
Canada) were tested as positive controls in concentrations ranging from 
0.01–1 nM and 4–9000 nM, respectively. The vehicle concentration was 
kept constant across the plate and never exceeded 0.1%. The assay was 
terminated with the Dual-Glo® Luciferase Assay System (Promega, WI, 
US) to measure both Firefly and Renilla luciferase activity on a lumin-
ometer (BioOrbit, Galaxy). Chemicals were tested across three inde-
pendent experiments, each run with three technical replicates. Means of 
technical replicates from independent biological experiments were 
pooled. All treatment concentrations leading to >20% decreased cell 
viability compared to vehicle control were perceived as cytotoxic and 
omitted from the dataset before further analysis. 
2.3. Animal study 
The animal experiment had ethical approval from the Danish Animal 
Experiments Inspectorate (license number 2015-15-0201-00553). Two 
blocks of 12 time-mated Crl:CD(SD) rats (Charles River, Germany, via 
SCANBUR, Karlslunde, Denmark), 9 weeks old, weighing 200–250 g, 
were delivered to the animal facility at the Technical University of 
Denmark on gestational day (GD) 3 (the day following overnight mating 
was denoted GD1). Dams were divided into three groups of four animals 
with similar body weight (bw) distribution on GD4. The animals were 
housed in pairs until GD17, and thereafter single-housed in High Tem-
perature polysulfone cages with wood chip bedding, nesting material 
and a wooden shelter (Tapvei, Denmark). The polysulfone bottles and 
cages as well as the aspen wood shelters (instead of plastic shelters) were 
used to reduce the risk of migration of BPA that potentially could 
confound the study results. Animals were kept under standard condi-
tions with 12 h light/dark cycles, in ScanTainers (Ventilated Cabinets 
from SCANBUR) with 50–60 air changes per hour at 22 ◦C ± 10 and 
humidity kept at 55% ± 5. Animals were fed Altromin 1314 (Altromin 
GmbH, Lage, Germany, soy and alfalfa-free) and tap water in Bisphenol 
A-free bottles (Polysulfone 700 mL, 84-ACBT0702SU Tecniplast, VA, 
Italy) ad libitum. 
Dams were acclimatized for four days before starting exposure on 
GD7. Dosing was initiated first at GD7 to avoid implantation loss, yet 
early enough to cover early fetal developmental stages and throughout 
the sensitive periods for reproductive development. The rats were 
weighed and gavaged each morning with vehicle (corn oil, CAS no.: 
8001-30-7, Sigma-Aldrich, Søborg, Denmark, product no.: C8267–2.5 L, 
lot-nr.: MKCG3257) or clotrimazole (25 or 75 mg/kg bw/day) until 
GD21. Doses of 25 and 75 mg/kg bw/day were selected as these were the 
highest achievable doses not expected to induce maternal toxicity 
(Bayer HealthCare, 2006). The dams were given a dosing volume of 2 
mL/kg bw. 
2.4. Necropsy 
On GD21, dams were gavaged 1 h ± 15 min before decapitation 
under CO2/O2-anesthesia. Maternal trunk blood was collected in 
heparin-coated vials and the liver was taken out and weighed. Uteri 
were collected, weighed, and the number of resorptions, implantations, 
live fetuses, and the location in uterus, were registered. Any anomalies 
and the body weight of the fetuses were recorded and the anogenital 
distance (AGD) was measured using a stereomicroscope with a micro-
meter eyepiece by an experienced technician blinded with respect to 
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treatment groups. Fetal trunk blood was collected in heparin-coated 
vials, pooled for each sex within each litter. All blood samples were 
kept on ice before centrifugation at 4000 rpm at 4 ◦C for 10 min after 
which the plasma was transferred to new tubes and stored at − 80 ◦C. 
Fetal rat testes were harvested under a stereomicroscope and 
immediately snap frozen in liquid nitrogen, or placed in Bouin’s fixative, 
formalin, or RNA-later. Tissue in Bouin’s fixative was transferred to 50% 
ethanol the following day (day 2), 70% on day 3 and run on an Excelsior 
AS Tissue Processor (Thermo Scientific™) on day 4 before paraffin 
embedding. Tissue in formalin was run on the tissue processor on day 4 
before paraffin embedding. Tissue in RNA-later was stored at − 80 ◦C. 
2.5. Chemical analysis of clotrimazole in fetal plasma 
Clotrimazole concentration in fetal plasma was measured by Liquid 
Chromatography-Mass Spectrometry (LC-MS) as previously described 
(Draskau et al., 2019). External calibration standards were used for 
quantification. This means that the concentrations determined in plasma 
samples are semi-quantitative since correction for loss during extraction 
and analysis are not fully corrected. Plasma samples were mixed with 
acetonitrile and Isolute C18 sorbent, vortexed and incubated at 4 ◦C for 
30 min before centrifugation at 10,000 xg for 10 min at 4 ◦C. Prior to 
analysis supernatants were mixed with 75% acetonitrile. 
LC was performed on a Dionex Ultimate 3000 RS (Thermo Scienti-
fic™) with a Poroshell SB C-8 (100 × 2.1 mm, 2.7 μm particle size) 
column held at 40 ◦C (Agilent technologies, Walbron, Germany). The 
solvent system (ammonium hydroxide, formic acid, and acetonitrile), 
programming, and flow rate were setup as described in (Draskau et al., 
2019). 
The LC system was connected to a Bruker Daltonics, maXis qTOF MS 
equipped with an electrospray ion source operated in positive ion mode 
(Bruker Daltonics, Bremen, Germany). Sodium formate dissolved in 50% 
2-propanol was introduced in the ion source in a 0.2–0.4 min time 
segment and used for internal calibration of the data files. Hexakisper-
flouroetoxyphophazene was used as lock mass calibrant to compensate 
for drift in the mass axis during analysis. 
External standard samples were prepared by diluting standard so-
lutions with milli Q water at six different levels in the concentration 
range of 0 to 1000 ng/mL clotrimazole. Standards and blanks were 
analyzed in the beginning of a sequence and after each set of samples. 
The ion source settings were: dry gas temperature 200 ◦C, nebulizer 
pressure 2 bars, capillary voltage 2500 V, drying gas flow 8 L/min. The 
scan range was from 80 to 700 m/z with an acquisition rate of 2 Hz. 
Data files were processed using QuantAnalysis (Bruker Daltonics, 
Bremen, Germany). Extracted ion chromatograms of m/z 277.078 ±
0.005 Da were constructed and integrated. Plasma concentrations were 
calculated based on linear calibration curves constructed using 1/x 
weighing. 
2.6. Plasma and testis steroid hormone analysis by HPLC-MS/MS 
Plasma and testis samples were analyzed for steroid hormone levels 
by LC-MS/MS as previously described (Hadrup et al., 2016). The 
extraction procedure and LC-MS/MS setup were performed as in 
(Draskau et al., 2019). 
Plasma samples were vortexed with formic acid in acetonitrile with 
3.33 ng/mL internal standard (deoxycortisol-d8 and cortisol-d4 from 
Cerilliant (TX, US), methyltestosterone-d3, beta-testosterone-d2, beta- 
estradiol-d3 and progesterone-c2 from Rikilt (Wageningen, 
Netherlands). Vials were incubated at − 20 ◦C for 20 min and centrifuged 
at 10,000 xg for 7 min at 4 ◦C before supernatants were mixed with 
Supel™ QuE Z-Sep powder (Supelco, PA, USA, #55418-U), shaken for 
60 s, and centrifuged for 3 min at 3500 xg. Supernatants were then dried 
by nitrogen evaporation before reconstitution with acetonitrile and 
water. 
For testes samples, one testicle was transferred to a beetBeater tube 
(Fischer Scientific, MA, USA) and 1 mL of 80% acetonitrile (with in-
ternal standards, 1 ng/mL) was added. The sample was homogenized for 
1 min and 50 mg of Que. Z-Sep (Sigma-Aldrich, MO, US) was added 
followed by whirlmix for 1 min. The sample was centrifuged at 3000 xg, 
4 ◦C for 10 min and placed at − 18 ◦C for 1 h. The sample was then 
centrifuged at 10,000 xg at 4 ◦C for 10 min, followed by filtration 
through a SPE column (Waters Corp., MA, US) (HLB, 30 mg), condi-
tioned with 2 mL 80% acetonitrile. The sample was evaporated to dry-
ness (50 ◦C, N2) and dissolved in 500 μL 10% acetonitrile. On-line-SPE 
LC-MS/MS was used for steroid hormone separation, detection, and 
quantification exactly as described in (Draskau et al., 2019). 
We detected 8 (bold) out of 14 hormones assayed for: testosterone, 
epi-testosterone, androstenedione, dehydroepiandrosterone (DHEA), 
dihydrotestosterone (DHT), corticosterone, cortisol, hydroxycortisol, 
deoxycortisol, pregnenolone, progesterone, hydroxyprogesterone, 
estradiol, and estrone. 
The limit of detection (LOD) and limit of quantification (LOQ) were 
estimated as the concentrations corresponding to three and 10 times 
signal-to-noise, respectively. LOQs were estimated to be 0.1 ng/mL for 
androstenedione, progesterone, testosterone, estradiol, and estrone, 0.2 
ng/mL for epi-testosterone, and 0.3 ng/mL for corticosterone and 
hydroxyprogesterone. For quantification, external calibration standards 
were run before and after the samples at concentrations of 0.02, 0.05, 
0.1, 0.2, 0.5, 1.0, 2.0, and 5.0 ng/mL, with 2.0 ng/mL internal standard. 
Blank plasma samples were spiked with analyte at three concentration 
levels: 0.0 (blank sample), 0.5, and 2.0 ng/mL and run for quality con-
trol. However, some measured values in the groups with high 
clotrimazole-exposure were below the LOQ or LOD. Values below the 
detection limit were set as LOD divided by the square root of 2. In fetal 
testes, the level of hydroxy-progesterone was below LOD in controls but 
increased dramatically with azole-exposure. Values below LOD in fetal 
testes were set as zero. 
The mass spectrometer was an EVOQ Elite Triple Quadropole In-
strument from Bruker (Bremen, Germany) and the UPLC system was an 
Ultimate 3000 system with a DGP-3600RS dual-gradient pump. Data 
handling was performed in MS Workstation v. 8.2.1 software. 
2.7. Histopathology 
One Bouin’s fixed, paraffin embedded testis from each litter in all 
dose groups (n = 7–8, 23 testes in total), was randomly selected for 
histopathological examination. Two sections per testis were evaluated 
(dose group blinded to observer) by light microscopy after Meyer’s he-
matoxylin and eosin (H&E) staining. Testes were assessed for the pres-
ence of Leydig cell clusters, edemas, multinucleated gonocytes, and 
testis cord dysmorphology. 
2.8. PBK model 
A generic physiologically-based pharmacokinetic (PBK) model was 
used to simulate age-dependent physiological and biochemical changes 
in rodents associated with ongoing pregnancy after repeated daily oral 
dosing (gavage) of clotrimazole. This basic flow-limited model was 
previously developed as part of a quantitative in vitro to in vivo extrap-
olation (QIVIVE) approach for predicting in vivo anti-androgenicity in 
male rats arising from gestational exposures (Scholze et al., 2020). In 
this model, the focus is on the simulation of internal exposure concen-
trations in the blood plasma of the fetus at GD15–18, which corresponds 
to the developmental stage considered most critical for male sexual 
differentiation in rats (Welsh et al., 2008). The PBK model includes the 
most relevant pharmacokinetic/dynamic compartments such as blood/ 
plasma, gut, liver, kidney, fat, placenta, fetus, and two remaining 
maternal compartments, which include all other well- or poorly- 
perfused organs and tissues lumped together. All clotrimazole-specific 
kinetic parameters were determined from public sources: i) the overall 
metabolic clearance rate was scaled from an in vitro intrinsic hepatic 
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clearance of 77.1 μL/min/million hepatocytes (U.S. Environmental 
Protection Agency, 2020; Williams et al., 2017) to 18.5 L/h for the 
simulation; ii) the unbound fraction in blood plasma was set to 0.01 
(Pearce et al., 2017); iii) the enterohepatic circulation from liver back to 
intestine was neglected by setting the biliary excretion rate to zero; iv) 
renal elimination was considered negligible due to high metabolic 
elimination and thus the urinary excretion rate fixed to zero; v) the 
blood-to-serum partition ratios were set to 1; vi) the tissue:plasma 
partition coefficients were derived from tissue-composition-based 
equations according to (Poulin and Theil, 2002). Quantitative details 
about the absorption from the gastrointestinal (GI) tract into the liver in 
rodents could not be retrieved from public literature. Pharmacokinetic 
studies in dogs show that only 10% of the orally administered dose 
reached the systemic circulation, but most of the substance is detectable 
in the feces (Conte et al., 1992). By use of these data, the uncertainty of 
the dog-to-rat extrapolation was operationalized by assuming that 
5–20% of the oral administered dose reached the internal system of the 
pregnant rat, with each value in the range considered as equally likely. 
In order to comply with the PBK model structure, the fecal excretion rate 
was fixed to zero and all intake doses were reduced by 80–95% in the 
PBK simulations. 
The plasma exposure concentration-time curve after the daily gavage 
is expected to be of short life, with 98% mass of the total integrated area 
under this curve (AUC) located within the first 12 h after each gavage. A 
fetal plasma concentration was approximated as the average concen-
tration over the time between GD15–18 and estimated as the area under 
the curve (AUC) divided by 36 h (i.e. the sum of all three 12-h periods 
after gavage). 
2.9. RNA extraction, cDNA synthesis and RT-qPCR analysis 
Total RNA was isolated using RNeasy Microkit (Qiagen, Hilden, 
Germany) and quantified on a Nanodrop-1000 Spectrophotometer. 
cDNA was synthesized from 500 ng RNA using the Omniscript RT kit 
(Qiagen, Hilden, Germany) according to manufacturer’s description. 
RT-qPCR was performed in duplicates on a QuantStudio 7 Flex Real- 
Time PCR System (Applied biosystems, CA, US) in 20 μL reaction vol-
umes containing TaqMan Fast Universal Master mix (Life Technologies, 
CA, US), 3 μL diluted (1:20) cDNA and gene specific TaqMan assays (Life 
Technologies, CA, US): Ddx4 (Rn01489814_m1), Sox9 
(Rn01751069_mH), Cyp11a1 (Rn00568733_m1) and Bcl-2 
(Rn99999125_m1). Data were analyzed with the comparative Ct method 
normalized with the geometric mean of two verified reference genes 
Sdha (Rn00590475_m1) and Rps18 (Rn01428913_gH). The suitability of 
these reference genes for the tissue in question was previously verified 
(Svingen et al., 2015) and were monitored for cross-sample stability (Ct- 
values) in the present study. 
2.10. Statistical analyses 
Data from the in vitro AR assay, analysis of in vivo internal clotri-
mazole concentrations, analysis of hormone levels in fetal plasma and 
testis, maternal parameters and litter data, as well as RT-qPCR data were 
assessed for normal distribution and homogeneity of variance by re-
sidual statistics. Data that were not normally distributed were log- 
transformed and assessed again. Data that were normally distributed 
were analyzed using one-way ANOVA followed by Dunnett’s post hoc 
test using GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA). 
Non-normally distributed data were analyzed by Kruskal-Wallis fol-
lowed by Dunn’s multiple comparison test using GraphPad Prism 8 
(GraphPad Software, San Diego, CA, USA). 
In vivo data on AGD, AGD index (AGDi; AGD/cube root of bw), and 
fetal body weight at GD21, were analyzed using one-way ANOVA fol-
lowed by Dunnett’s post hoc test using SAS® (SAS Enterprise Guide 8.2, 
SAS Institute, USA). Statistical analyses of AGD and AGDi were adjusted 
using litter as an independent, random and nested factor and analyzed 
using body weight as a covariate. Fetal body weights were analyzed 
using the number of offspring per litter as covariate. For these analyses, 
the litter was the statistical unit. 
3. Results 
3.1. Clotrimazole below cytotoxic levels does not affect AR activity in 
vitro 
Clotrimazole did not agonize or antagonize AR activity at non- 
cytotoxic concentrations (Fig. 1). Clotrimazole compromised cell 
viability from 0.4 μM, thus treatment groups above 0.2 μM were omitted 
from statistical analysis. 
3.2. Measured and modelled clotrimazole concentrations in fetal plasma 
Measured and PBK-simulated plasma levels of clotrimazole in male 
fetuses after gestational exposure (GD7–21) are shown in Fig. 2. Simu-
lations from the PBK-modelled relationship between fetal plasma con-
centrations of clotrimazole and doses administered to dams indicate that 
the fetal exposure levels at doses up to 100 mg/kg are expected to be 
well below 1 μM. If we assume that only a small amount of the dose 
reaches the systemic circulation (5% absorption), then the PBK model 
simulated fetal plasma levels around 10 nM, and at a higher absorption 
(20%) around 100 nM (illustrated in Fig. 2 by the red shaded areas 
reflecting least- and worst-case kinetic model assumptions for describing 
5% and 20% absorption). 
We could detect and quantify clotrimazole in all plasma samples 
from exposed GD21 male fetuses, with values ranging from 0.01 to 0.4 
μM. The median clotrimazole concentration in the 25 and 75 mg/kg bw/ 
day dose groups were 0.031 μM and 0.057 μM, respectively. Plasma 
concentrations varied greatly between fetuses (Fig. 2), with both the 
lowest (0.01 μM) and highest concentrations (0.40 μM) detected in the 
high-dose group. The measurements agreed relatively well with the PBK 
simulations, at least when a higher absorption was assumed in the ki-
netic model. It should be noted that samples were taken at a time where 
we expected the internal maternal levels to be around its peak of the 
concentration-time curve (1 h ± 15 min after gavage), meaning that 
inter-individual exposure measurements can vary significantly, even in 
the fetal compartment as observed at both doses. Furthermore, simu-
lated concentrations are expressed as average within the first 12 h after 
gavage, and therefore well below the peak levels of the concentration- 
time curve. 
Clotrimazole can inhibit both CYP17A1 and CYP19A1 in vitro within 
nanomolar concentration ranges (Munkboel et al., 2019). We used IC50 
estimates for both enzymes (obtained from the H295R cell assay) and 
compared them with the fetal levels of clotrimazole measured at GD21. 
Both the simulated and the measured fetal compartment concentrations 
in the 25 mg/kg bw/day and 75 mg/kg bw/day exposure groups 
exceeded the concentration associated with in vitro CYP17A1 inhibition 
(lower horizontal line depicting in vitro IC50 value in Fig. 2). Addition-
ally, for a few animals the measured fetal concentrations exceeded the 
concentration associated with CYP19A1 inhibition (upper horizontal 
line in Fig. 2). 
3.3. High orally-administered doses of clotrimazole induce moderate 
maternal toxicity 
We observed no external signs of maternal toxicity during the animal 
study, which was terminated at GD21. The body weights of pregnant 
dams in the high dose group were 11% lower than the control group at 
termination. The dams displayed a significantly lower bw gain from 
GD7–21 and the adjusted maternal bw (bw after subtraction of uterus 
weight) was significantly lower in both dose groups relative to controls 
(Table 1). Dam liver weights, and liver weights relative to bw, were 
significantly increased in the high dose group (Table 1) as compared to 
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controls. These livers displayed pale and speckled patches consistent 
with an increased induction of hepatic enzymes and hepatotoxicity in 
the dams from the high dose group. Effects on litter sizes and number of 
resorptions were not statistically significant in any exposure group. One 
occurrence of a very late resorption (around GD19), as well as one litter 
with a very high number of early resorptions (79% post-implantation 
loss), were observed in the highest exposure group. We observed no 
obvious signs of toxicological effects in the live fetuses, with both males 
and females having similar size and weight between dose groups 
(Table 1). AGD was not significantly different in clotrimazole-exposed 
fetuses compared to controls (Table 1). 
3.4. Clotrimazole exposure decreases maternal blood concentrations of 
progesterone and estrone 
In dam’s plasma, progesterone and estrone levels were lower at 
GD21 in the 75 mg/kg bw/day clotrimazole exposure group relative to 
controls. Estrone levels were also significantly lower in the 25 mg/kg bw 
exposure group (Fig. 3) when compared to control group. No statistically 
significant changes to dam androstenedione, corticosterone, testos-
terone, or estradiol were observed (Fig. 3). 
3.5. Intrauterine clotrimazole exposure decreases fetal blood estrogen and 
progesterone levels 
Estrone and progesterone levels were significantly lower in GD21 
male and female fetuses exposed to 75 mg/kg bw/day clotrimazole 
relative to control fetuses. In the male fetuses, estradiol levels were also 
lower in the high dose group and decreased in a linear dose-dependent 
manner (Fig. 4) relative to controls. We observed no changes for an-



























































































Fig. 1. Clotrimazole is not an in vitro AR antagonist. Clotrimazole was tested in the AR-Eco reporter gene assay for both agonistic and antagonistic activity, as well as 
cell viability. Bars represent pooled means from three independent experiments (N = 3; mean ± SEM) normalized to the vehicle control, set to 1. Treatment con-
centrations that compromised cell viability (C) with a threshold of 20% (horizontal line) were omitted from the datasets before statistical analysis. 
Fig. 2. Measured (GD21) and PBK simulated (GD15-GD18) plasma concen-
trations of clotrimazole in male fetuses after gestational exposure (GD7–21). 
PBK simulated fetal concentrations are shown as a red shaded area reflecting 
least- and worst-case kinetic model assumptions for describing 5% and 20% 
absorption (see Materials and Methods). Symbols (●) show the measured fetal 
plasma levels for each litter taken from male fetuses 1 h ± 15 min. After gavage 
(pooled from 4 to 11 fetuses per litter) with mean levels at 0.051 ± 0.018 μM 
after 25 mg/kg bw/day and 0.150 ± 0.069 μM after 75 mg/kg bw/day. Hori-
zontal solid lines show the concentrations associated with strong in vitro 
CYP19A1 and CYP17A1 activities (IC50), and the dashed line indicates the 
analytical limit of quantification (LOQ) for the plasma concentration mea-
surements. (For interpretation of the references to colour in this figure legend, 
the reader is referred to the web version of this article.) 
Table 1 
Pregnancy and litter data. Data represent group means ± SD, based on litter 
means.   
Control Clotrimazole Clotrimazole 
25 mg/kg bw/ 
day 
75 mg/kg bw/ 
day 
GD21 Caesarean section    
No. of litters N = 8 N = 8 N = 8 
Maternal bw (g), GD7 257.3 ±
19.1 
256.4 ± 13.3 253.8 ± 20.9 
Maternal bw (g), GD21 385.0 ±
24.0 
366.1 ± 22.8 343.3 ± 35.9 




109.7 ± 13.2 89.5 ± 27.4 




272.4 ± 11.3 264.4 ± 17.4 
Maternal liver weight, GD21 14.1 ± 1.3 14.7 ± 1.2 18.8 ± 2.7 




0.04 ± 0.002 0.06 ± 0.003 
No. of fetuses 14.1 ± 1.5 13.6 ± 2.6 11.9 ± 4.2 
No. of resorptions 0.8 ± 1.0 0.8 ± 1.0 2.0 ± 3.7 
% postimplantation loss 4.8 ± 6.6 5.3 ± 6.8 14.6 ± 26.7 
Fetal bw male (g) 4.1 ± 0.3 4.4 ± 0.3 3.99 ± 0.3 
Fetal bw female (g) 3.8 ± 0.3 4.2 ± 0.3 3.8 ± 0.4 
Male AGD (mm) 3.89 ± 0.1 3.95 ± 0.2 3.91 ± 0.1 
Male AGD index 2.44 ±
0.05 
2.41 ± 0.07 2.50 ± 0.08 
Female AGD (mm) 2.15 ± 0.1 2.19 ± 0.1 2.23 ± 0.2 
Female AGD index 1.38 ±
0.04 
1.36 ± 0.08 1.44 ± 0.14 
Values in bold are statistically significantly different from Control. 
AGD (mm) was analyzed with fetal weight as covariate. 
AGD index = AGD divided by cube root of the bodyweight. 
a Adjusted maternal bw (g) is bw at GD 21 after subtracting the uterus weight. 
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3.6. Intrauterine clotrimazole exposure increases intratesticular levels of 
hydroxy-progesterone 
In utero exposure to 75 mg/kg bw/day of clotrimazole elevated fetal 
testis hydroxy-progesterone at GD21 (Fig. 5) when compared to control 
group. No significant changes to testis progesterone, androstenedione, 
corticosterone, testosterone, or epi-testosterone were observed (Fig. 5). 
3.7. Intrauterine clotrimazole exposure at human-relevant concentrations 
do not adversely affect testis histology or marker gene expression 
Histopathological examination of GD21 testes revealed no gross 
changes to testis histology after in utero clotrimazole exposure. We 
detected no obvious signs of edemas, testis cord dysmorphology, Leydig 
cell hyperplasia or multinucleated gonocytes (Fig. 6). In general, the 
exposed testes displayed same histology as control testes. 
To further support the observation that testis integrity was main-
tained, we tested a small number of gene transcripts for potential dys-
regulation. We included the germ cell marker Ddx4, the Sertoli cell 
marker Sox9, the Leydig cell marker Cyp11a1 and the apoptosis-related 
marker Bcl-2. Neither of the four genes were affected by clotrimazole 
exposure relative to controls (Fig. 7). 
4. Discussion 
A recent study reported that the widely used, non-prescription 
antifungal drug clotrimazole can inhibit steroidogenesis in vitro at 
doses relevant for human exposure (Munkboel et al., 2019). Further-
more, a human study indicated possible anti-androgenic effects in boys 
born to mothers using clotrimazole during pregnancy (Mogensen et al., 
2017). Together, these two studies warrant concern about potential 
indiscriminate use of antifungal medicines containing clotrimazole 
during pregnancy. To start addressing this concern, we performed an 
intrauterine exposure study in rats to specifically look at potential effects 
on steroid hormone profiles and the anti-androgenic effect biomarker 
AGD. We show that clotrimazole can significantly alter the steroid 
hormone profile in rat fetuses exposed in utero to human-relevant doses, 
whereas AGD was not significantly affected in the same male fetuses. 
Many azoles are potent disruptors of human steroidogenesis in vitro 
(Draskau et al., 2019; Karmaus et al., 2016; Kjærstad et al., 2010; 
Munkboel et al., 2019; Taxvig et al., 2013). Many can also inhibit 
androgen receptor (AR) activity in vitro (Draskau et al., 2019; Kjærstad 
et al., 2010). Since effects of clotrimazole have already been determined 
in the H295R steroidogenesis assay (Karmaus et al., 2016; Munkboel 
et al., 2019), we supplemented the in vitro profiling by testing for po-
tential effects on the AR using the human AR-EcoScreen™ assay. As we 
observed neither agonistic nor antagonistic effects at concentrations 
below cytotoxic levels, it is likely that the main modality by which 
clotrimazole exert endocrine disrupting activities is as a steroidogenesis 
disruptor. 
Based on a previous study showing potential, albeit non-significant, 
short male AGD in infant boys after intrauterine exposure (Mogensen 
et al., 2017), we specifically aimed to see if human-relevant exposure to 
clotrimazole could induce shorter male AGD in male rat fetuses. In our 
study, intrauterine exposure to clotrimazole did not induce short male 
AGD. This lack of response is in agreement with the observation that 
testosterone levels were unchanged and that clotrimazole does not 
inhibit AR activity, corresponding with what we know about effects of 
anti-androgenic chemicals on AGD (Schwartz et al., 2019). 
Significantly decreased estrone concentrations were seen in plasma 
of both dams and fetuses. In male fetuses, this decrease was accompa-
nied by a linear dose-dependent decrease in estradiol concentrations. 
These observations are in line with a potent inhibitory effect on aro-
matase (CYP19A1), the enzyme responsible for androgen to estrogen 
conversion. Even though our PBK model did not predict fetal clotrima-
zole concentrations reaching concentrations corresponding to the IC50 
for CYP19A1 inhibition, we did observe fetal plasma concentrations 
exceeding this value. This mode of action – aromatase inhibition – is 
seen for many azole fungicides (Andersen et al., 2002; Trösken et al., 
2006; Vinggaard et al., 2000; Zarn et al., 2003) and has also been 
observed previously for clotrimazole in vitro (Mason et al., 1985; 
Munkboel et al., 2019). Our study indicates that maternal exposure to 
doses of 75 mg/kg bw/day can induce fetal clotrimazole concentrations 
reaching and exceeding the IC50 for aromatase inhibition leading to 
significantly lower plasma estrogen concentrations in rats. 
Concomitant with decreased estrogen concentrations, progesterone 
concentrations were also decreased in plasma of dams and fetuses in 
response to clotrimazole exposure. Both estrogen and progesterone are 
important regulators of pregnancy and parturition, and chemical- 
induced disruptions of estrogen and progesterone levels can induce 
post-implantation loss, including late resorptions in both rodents and 
primates (Albrecht et al., 2000; Stinchcombe et al., 2013; Taxvig et al., 
2008, 2007). We also observed a few cases of post-implantation loss and 
a very late resorption in dams in the high dose group. Estrogen and 
progesterone disruption in women would also be of concern with clo-
trimazole use during pregnancy. 
The observed changes to steroid hormone concentrations following 
exposure to clotrimazole is not only relevant for pregnancy outcomes. 
The balance between androgen and estrogen levels during fetal life is 
also important for reproductive development, at least for the external 
genitalia (Cripps et al., 2019; Govers et al., 2019; Hess et al., 2021; 
Mattiske and Pask, 2021; Sathyanarayana et al., 2012; Zheng et al., 
2015). Limited by our study design, we could not assess postnatal male 
pups for gross genital abnormalities. General assessments of GD21 male 
fetuses, however, did not reveal any obvious genital malformations. 
Thus, although we may speculate that the hormonal changes induced by 
our administered doses of clotrimazole are not sufficient to induce gross 
malformations to the genitals, we cannot exclude the possibility that 
Fig. 3. Clotrimazole exposure affects steroid hormone concentrations in preg-
nant rats. Maternal blood plasma steroid hormone levels at gestational day (GD) 
21 (ng/mL), following daily exposure from GD7. *p < 0.05. Dams were exposed 
(GD7–21) to vehicle (Ctrl), 25, or 75 mg/kg bw/day of clotrimazole. Results are 
shown as mean ± SEM (n = 8). 
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similar hormone disruption can contribute to milder effects in humans. 
We also profiled intratesticular steroid hormones in the GD21 male 
fetuses. At this developmental stage, estrogen concentrations were too 
low to detect, which is consistent with the very low aromatase levels 
observed at this stage. This suggest that changes to estrone levels in male 
plasma is caused by disruption to adrenal steroidogenesis, a point that 
should be addressed in future studies. Notably, we also observed a large 
increase in hydroxy-progesterone, which is barely detectable in control 
testes. This effect is in contrast to what we observed in blood and could 
be the result of a systemic feedback mechanism – e.g. low maternal and 
fetal estrogen levels causing increased gonadotropin production. 
Regardless, hydroxy-progesterone is significantly affected in 
clotrimazole-exposed male fetuses, but any potential adverse conse-
quences of this are difficult to surmise since there is limited background 
knowledge available. Prenatal exposure to progesterone can increase 
expression of genes important for Leydig and Sertoli cell function in 
sheep (Siemienowicz et al., 2020), affect sperm quality in rodents 
(Ahmed et al., 2020; Harini et al., 2009), and induce morphological and 
histological changes in rat testes (Ahmed et al., 2016) but we observed 
no testicular histopathological changes, nor changes to expression of 
selected marker genes at GD21. 
In this study, we detected clotrimazole in fetal plasma at GD21. Since 
exposure route was via dams, clotrimazole can clearly cross the rat 
placental barrier and directly expose the fetus. In humans, plasma 
concentrations of clotrimazole following therapeutic dosing of 50–500 
mg/day as vaginal tablets have been reported in the range of 0.03–0.09 
μM (Kragie et al., 2002; Munkboel et al., 2019; Ritter et al., 1982). In our 
study, the mean male fetal plasma concentration in the high dose group 
(75 mg/kg bw/day) was 0.15 μM, which is only 1.7-fold higher than 
maximum plasma concentration measured in the human subjects of 
0.09 μM (Ritter et al., 1982). Notably, the fetal rat plasma clotrimazole 
concentrations measured in our study were within the 0.03–0.09 μM 
range. Thus, we observed significant disruption to both maternal and 
fetal steroid hormone profiles at human therapeutically relevant con-
centrations, albeit these human ranges relates to women and not 
necessarily human fetal plasma levels. Indeed, even if assuming that 
clotrimazole levels in human fetuses would approach those observed in 
women, it has been established that clotrimazole is rapidly metabolized 
(Ritter et al., 1982). 
5. Concluding remarks 
Clotrimazole is a widely used, non-prescription azole fungicide used 
to treat various fungal infections, including vaginal mycosis. Since many 
azoles are known to be endocrine disruptors, there is some concern than 
indiscriminate use by pregnant women could disrupt fetal hormone 
signaling and cause adverse health effects in the offspring. There are 
some epidemiological data indicating potential anti-androgenic effects 
of clotrimazole, with a trend towards shorter AGD in male boys asso-
ciated with intrauterine exposure. In our rat study, we did not observe a 
significant effect on AGD in male rat offspring at exposure concentra-
tions observed in exposed humans. Another study has shown that clo-
trimazole can act as a strong steroidogenesis inhibitor in vitro at the same 
human-relevant concentrations. We also observed significant changes to 
steroid hormones in the rat fetuses at similar exposures, thus demon-
strating that clotrimazole can disrupt sex hormone levels in vivo at these 
dose levels. Considering these human and animal data together, there is 
some concern about sex hormone disruption in fetuses of pregnant 
women self-medicating with clotrimazole. However, since systemic 
maternal clotrimazole is rapidly metabolized, it is unclear whether 














































































































































Fig. 4. Maternal clotrimazole exposure affects steroid hormone concentrations in male and female rat fetuses. Pregnant rats were exposed from gestational day (GD) 
7–21, and steroid hormone levels measured in blood plasma (ng/mL) at GD21. Rats were exposed to vehicle (Ctrl), 25, or 75 mg/kg bw/day of clotrimazole. Results 
are shown as mean ± SEM of pooled samples from 6 to 8 litters per group (n = 6–8); *p < 0.05. 
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human fetal concentrations are high enough to pose a risk of developing 
adverse reproductive defects. If applying a more cautionary viewpoint, 
the use of clotrimazole during pregnancy should probably be limited, as 
altered hormone levels could be problematic for both mother and fetus, 
not least if combined with exposure to other EDCs. 
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Fig. 5. Maternal clotrimazole exposure affects intratesticular steroid hormone 
concentrations in male fetuses (ng/testis). Fetuses were exposed via mothers 
from GD7–21 to vehicle (Ctrl), 25, or 75 mg/kg bw/day of clotrimazole. Results 
are shown as mean ± SEM (n = 7–8 testes per group, each from different lit-
ters). *p < 0.05. 
Fig. 6. Maternal exposure to clotrimazole does not adversely affect fetal testis 
histology. Fetuses were exposed via mothers from GD7–21 to vehicle (Control), 
25, or 75 mg/kg bw/day of clotrimazole. GD21 testes were stained with H&E 
and analyzed by brightfield. Histopathological evaluation did not reveal any 
gross signs of histological aberrations compared to control testes. N = 6–8 testes 

















































































Fig. 7. Maternal exposure to clotrimazole does not affect expression of selected 
fetal testis marker genes. Fetuses were exposed via mothers from GD7–21 to 
vehicle (Ctrl), 25, or 75 mg/kg bw/day of clotrimazole. RT-qPCR analyses of 
the germ cell marker Ddx4, the Sertoli cell marker Sox9, the Leydig cell marker 
Cyp11a1 and the apoptosis-related gene Bcl-2 were unchanged in exposed GD21 
testes relative to controls. N = 6–8 testes per treatment group. 
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